NIKKEI 225
38,923.03 +435.13 (+1.13%) HANG SENG
18,403.04 +323.43 (+1.79%) CRUDE OIL
74.37 -2.62 (-3.40%) GOLD FUTURES
2,362.50 +16.70 (+0.71%) DOW
38,292.57 -393.75 (-1.02%) Bitcoin GBP
54,125.33 +921.95 (+1.73%)
LEGN Jan 2025 35.000 put
| Previous close | 2.5600 |
| Open | 2.6000 |
| Bid | 1.9500 |
| Ask | 4.5000 |
| Strike | 35.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.3900 - 2.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
Business WireLegend Biotech to Participate in the Jefferies Global Healthcare Conference
SOMERSET, N.J., May 29, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m. ET.
Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
SOMERSET, N.J., May 23, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new and updated data from the CARTITUDE clinical development program evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for patients with multiple myeloma will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Association’s (EHA) Hybrid Congress.
- GuruFocus.com
Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...
Discover how Legend Biotech's robust Q1 performance and strategic initiatives are setting the stage for sustained growth.
